ArticleCancer causes & control : CCC2016
Underutilization of gene expression profiling for early-stage breast cancer in California.
Article in Cancer causes & control : CCC, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study.Breast cancer research and treatment · 2025Article
- Socioeconomic- and Insurance-Based Inequities in Oncotype DX Testing and Score-Guided Treatment.Cancer medicine · 2025Article
- Article
- Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Socioecologic Factors and Racial Differences in Breast Cancer Multigene Prognostic Scores in US Women.JAMA network open · 2024Article
- Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.Breast cancer research and treatment · 2023Article
- Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer.International journal of environmental research and public health · 2023Review
- Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer.Cancer medicine · 2023Article
- Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age.Breast cancer research and treatment · 2022Article
- Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review.Journal of personalized medicine · 2022Article
- Hospital Rurality and Gene Expression Profiling for Early-Stage Breast Cancer among Iowa Residents (2010-2018).The breast journal · 2022Article
- Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.International journal of environmental research and public health · 2021Article
- Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.Breast cancer research and treatment · 2020Article
- Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.Breast cancer research and treatment · 2020Article
- First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting.JNCI cancer spectrum · 2019Article
- Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.NPJ breast cancer · 2019Article
- Critical Lessons From High-Value Oncology Practices.JAMA oncology · 2018Article
- Disparities in quality of cancer care: The role of health insurance and population demographics.Medicine · 2017Article
- Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.Breast cancer research : BCR · 2017Article
- Progress in the clinical detection of heterogeneity in breast cancer.Cancer medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo describe the utilization of gene expression profiling (GEP) among California breast cancer patients, identify predictors of use of GEP, and evaluate how utilization of GEP influenced treatment of early-stage breast cancer.
methodsAll women diagnosed with hormone-receptor-positive, node-negative breast cancer reported to the California Cancer Registry between January 2008 and December 2010 were linked to Oncotype DX (ODX) assay results.
resultsOverall, 26.7 % of 23,789 eligible patients underwent the assay during the study period. Women age 65 or older were much less likely than women under age 50 to be tested (15.1 vs. 41.4 %, p < 0.001). Black women were slightly less likely and Asian women were slightly more likely than non-Hispanic white women to undergo GEP with the ODX assay (22.2 and 28.9 vs. 26.9 %, respectively, p < 0.001). Patients residing in low SES census tracts had the lowest use of the test (8.9 %), with the proportion increasing with higher SES category. Women with Medicaid health insurance were less likely than other women to be tested (17.7 vs. 27.5 %, p < 0.001). Receipt of adjuvant chemotherapy (ACT) was associated with the ODX recurrence score, although only 63 % of patients whose recurrence scores indicated a high benefit received ACT. Of patients not tested, 15 % received ACT.
conclusionsNearly three-fourths of eligible breast cancer patients in California during the 3-year period 2008 through 2010 did not undergo GEP. As a result, it is likely that many women unnecessarily received ACT and suffered associated morbidity. In addition, some high-risk women who would have benefited most from ACT were not identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.